Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a calcium channel blocker chemically unrelated to others such as diltiazem, nifedipine or verapamil. It is used in the treatment of angina pectoris. Oral administration.
At latest update no published data were found on excretion into breast milk.
Its high plasma protein-binding capacity makes it unlikely the passage to the breast milk, however, it has a very long elimination time.
It can cause QT prolongation on the EKG and serious cardiac arrhythmias. It has been withdrawn from the market in many countries.
During breastfeeding an alternative drug that is known to be safer is preferred, especially during the neonatal period and in case of a premature infant.